Third Expansion of IDEXX's Catalyst Platform in Under a Year Delivers Critical Insights to Veterinarians Evaluating Canine Patients for Endocrine Disorders
Addison's disease, often called "the great pretender," is a life-threatening condition caused by low cortisol and is difficult to diagnose due to its common and nonspecific clinical signs that can resemble those of other illnesses, such as gastroenteritis or kidney disease. Early detection is critical, as timely treatment can be lifesaving. Cushing's syndrome, driven by excess cortisol, is a common endocrine disorder in older dogs, and certain breeds are at an increased risk. Cushing's syndrome requires long-term management, and if left untreated, it can significantly diminish quality of life.
IDEXX's Catalyst Cortisol Test enables veterinarians to confidently and accurately diagnose or rule out Addison's disease and Cushing's syndrome during the patient visit, allowing for immediate treatment or adjustments to ongoing care management. This workflow efficiency continues throughout the patient journey with monitoring capabilities that enable tailored treatment adjustments, improving long-term care for patients with Cushing's syndrome.
"The Catalyst Cortisol Test is an accurate and highly requested test that addresses a critical need for our customers and equips veterinarians with built-in results interpretation for prompt action, supporting better health outcomes for dogs," said Jay Mazelsky, President and Chief Executive Officer of IDEXX. "Continuing to expand the Catalyst platform reinforces our Technology for Life promise, offering our customers solutions that advance in capabilities over time to expand clinical insights and care delivery at the point-of-care."
The IDEXX Catalyst Cortisol Test features:
Accuracy: Provides quantitative results in-clinic that align with IDEXX Reference Laboratories, enabling veterinarians to confidently diagnose or rule out Addison's disease and Cushing's syndrome.
Interpretive guidance: Integrates with the IDEXX Vetlab ® Station and VetConnect ® PLUS, providing results-specific interpretation in real-time during the patient visit.
Efficiency: The Catalyst Cortisol Test's load-and-go workflow can run alone or with additional chemistry tests using a single sample for comprehensive diagnostic insights into patient health status. This workflow saves hands-on sample preparation time for veterinary technicians and ensures repeatable results.
"A reliable in-house test is game-changing—it enables faster diagnosis and treatment of a life-threatening Addisonian crisis in dogs," said Patty Lathan, VMD, MS, DACVIM (SAIM).* "Additionally, by delivering accurate results during the visit, it supports timely care and streamlines daily workflows for busy veterinary teams."
The Catalyst Cortisol Test will be available in the U.S. and Canada at the end of July 2025, with a global rollout to the installed base of more than 75,000 Catalyst chemistry analyzers expected to start in the third quarter of 2025. For more information, visit the IDEXX Catalyst test menu web page.
About IDEXX
IDEXX Laboratories, Inc., is a global leader in pet healthcare innovation. Our diagnostic and software products and services create clarity in the complex, constantly evolving world of veterinary medicine. We support longer, fuller lives for pets by delivering insights and solutions that help the veterinary community around the world make confident decisions—to advance medical care, improve efficiency, and build thriving practices. Our innovations also help ensure the safety of milk and water across the world and maintain the health and well-being of people and livestock. IDEXX Laboratories, Inc. is a member of the S&P 500® Index. Headquartered in Maine, IDEXX employs approximately 11,000 people and offers solutions and products to customers in more than 175 countries and territories. For more information about IDEXX, visit: www.idexx.com.
Note Regarding Forward-Looking Statements
This news release contains or may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by the use of words such as "expects," "may," "anticipates," "intends," "would," "will," "plans," "believes," "estimates," "should," "project," and similar words and expressions. These forward-looking statements are intended to provide our current expectations or forecasts of future events; are based on current estimates, projections, beliefs, and assumptions; and are not guarantees of future performance. Actual events or results may differ materially from those described in the forward-looking statements. These statements are subject to risks, uncertainties, assumptions, and other important factors. Readers are cautioned not to put undue reliance on such forward-looking statements because actual results may vary materially from those expressed or implied. The reports filed by IDEXX pursuant to United States securities laws contain discussions of some of these risks and uncertainties. IDEXX assumes no obligation to, and expressly disclaims any obligation to, update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise. Readers are advised to review IDEXX's filings with the United States Securities and Exchange Commission (which are available from the SEC's EDGAR database at sec.gov and via IDEXX's website at idexx.com).
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Cision Canada
6 hours ago
- Cision Canada
Renewed definition of healthcare quality helps guide system improvement
CALGARY, AB, July 16, 2025 /CNW/ - Alberta has a renewed, evidence-based definition for healthcare quality released today by Health Quality Alberta, marking the first update to this important concept in nearly 20 years. The definition includes seven dimensions of quality: people-centred, accessible and timely, safe, integrated, equitable, effective, and efficient and sustainable. This new publication, Alberta Quality Dimensions for Health, updates and replaces one of Health Quality Alberta's most accessed resources: the Alberta Quality Matrix for Health. "How we define quality healthcare is the very foundation of everything else we do in planning and delivering healthcare services," says Dr. David Zygun, acting chief executive officer of Health Quality Alberta. "The definition of quality serves as a starting point, guiding decision-making and delivery of care. When people agree on what quality care looks like, they are more likely to be aligned on how to fund, plan, measure, and deliver quality, integrated care across the system." The new dimensions replace the definition of quality that was first introduced with the Alberta Quality Matrix for Health in 2005. Important changes include adding the dimensions of people-centred and equitable, for example, and expanding the meaning of safe care to include all forms of safety – not just physical, but also cultural and data-related, to name two forms. The dimensions can be applied at system, organizational, and care-delivery levels, informing policy, strategy, and design for the healthcare system. They give organizations and teams a common language that shifts their thinking and practice toward integrated people-centred care. This update brings together input from system partners across Alberta, patient advisors, and communities, along with insights from leading frameworks in use within and beyond Alberta and Canada. "As our name shows, we are in the business of health quality," says Dr. Zygun. "I'm pleased we can provide this important update to our health system partners. This establishes a benchmark for quality and a common language to support quality improvement."
Cision Canada
8 hours ago
- Cision Canada
Springbok Analytics Publishes Predictive Disease Progression Model for Muscular Dystrophy
AI-based digital twin modeling predicts patient-specific decline, addressing key trial design and biomarker challenges in FSHD CHARLOTTESVILLE, Va, July 16, 2025 /CNW/ - Springbok Analytics, a leader in AI-driven muscle analytics, today announced the publication in Scientific Reports of a new disease progression model for facioscapulohumeral muscular dystrophy (FSHD). Springbok's model employs a machine learning–based approach that predicts patient-specific muscle decline, functional outcomes, and fat infiltration using data derived from whole-body MRI. Click here to read the full paper. Facioscapulohumeral muscular dystrophy (FSHD) is a progressive, genetic neuromuscular disorder affecting approximately 1 in 7,500 individuals. It is driven by the aberrant expression of the DUX4 protein, which leads to skeletal muscle wasting and functional decline. Although conventional clinical endpoints, such as the 6-minute walk test (6MWT), Timed Up and Go (TUG), and reachable workspace (RWS), are commonly used to monitor disease progression, these measures often lack sensitivity in short-duration trials due to high variability and patient heterogeneity. The recent inability of RWS to differentiate outcomes in a Phase III FSHD trial further underscored these limitations. "Traditional functional metrics are simply not the best way to measure disease given the complexity and heterogeneity of FSHD," said Silvia Blemker, Ph.D., Chief Scientific Officer and Co-Founder at Springbok Analytics. "What we've shown in this study is that muscle MRI, combined with advanced machine learning, can capture that complexity and make it actionable, supporting more sensitive, predictive, and patient-specific trial designs." Springbok's advanced modeling combines baseline imaging biomarkers with clinical and functional data to predict how an individual's disease will progress. The result is a patient-specific simulation, or "digital twin," capable of forecasting future declines in muscle structure and performance. This approach outperforms current methods that rely on pooled muscle group metrics or single-slice measurements, which can dilute signal and miss early changes. "FSHD doesn't follow a predictable pattern from person to person, and treating every patient as if they use the same muscles in the same way prevents therapeutic breakthroughs," said Scott Magargee, CEO and Co-Founder at Springbok Analytics. "Our team has built a model that learns from each person's muscle composition, clinical markers, and functional data to simulate how their disease may progress, establishing a foundation for digital twins and synthetic control arms that is exciting for not only the FSHD community but many other populations that could benefit from precision healthcare." Study Highlights: Personalized Prediction: The model accurately forecasted annual changes in fat fraction (a marker of muscle tissue replacement) and lean muscle volume using baseline MRI data. Functional Correlation: Model predictions aligned with changes in TUG time, a standard test of lower-body mobility, linking imaging biomarkers to meaningful, patient-relevant outcomes. Enhanced Sensitivity: The study revealed detailed spatial patterns of muscle degradation not visible in grouped or averaged analyses. "The model doesn't just predict what might happen," added Blemker. "It tells us why, where, and how fast it's happening for each individual. That's a powerful shift in how we approach trial design, and ultimately, how we understand muscle disease biology." Springbok's AI-powered platform, which received FDA 510(k) Clearance last year, rapidly analyzes dozens of individual muscles from a single MRI scan, quantifying volume, asymmetry, and fat infiltration. The technology is already integrated into multiple neuromuscular trials, including a first-in-human study of Epicrispr Biotechnologies' investigational therapy, EPI-321. As interest in MRI biomarkers grows across rare and neuromuscular disease trials, this publication establishes a framework for incorporating high-resolution, AI-powered models into trial design, patient stratification, and biomarker development. To explore how Springbok's platform can support your trial or development program, contact: [email protected]. About Springbok Analytics: Springbok Analytics is a leading muscle health analytics company dedicated to advancing health and performance outcomes through innovative, AI-driven solutions that deliver a clearer, more comprehensive view of muscle health. Built on more than 15 years of research and scientific validation, Springbok's FDA-cleared technology transforms MRI data into personalized, 3D visualizations of muscle health. These detailed analyses provide precise metrics, including individual muscle volume and composition, fat infiltration, asymmetries, scar tissue, edema, and tendon morphology. By offering a more accurate and complete understanding of musculoskeletal health, Springbok enhances diagnostic accuracy, treatment monitoring, research capabilities, and performance optimization.
Cision Canada
9 hours ago
- Cision Canada
Oncolytics Biotech® Presents Aggregated Translational Data Providing Evidence of Pelareorep's Effectiveness Across Multiple Tumor Types
Integrated biomarker analyses confirm viral replication, interferon signaling, and a surge in tumor-infiltrating lymphocytes after pelareorep treatment Cross-study data show pelareorep increases PD-L1 expression and boosts cytotoxic T-cell activity, priming resistant tumors for checkpoint inhibitors SAN DIEGO and CALGARY, AB, July 16, 2025 /CNW/ -- Oncolytics Biotech ® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, summarized its biomarker and translational data for pelareorep, the Company's systemically delivered oncolytic virus. The data support pelareorep's mechanism of action and further strengthen the unique biological rationale and therapeutic potential for pelareorep as a platform immunotherapeutic. These include its ability to replicate in cancer cells, activate immune pathways, and drive T cell expansion and tumor infiltration in immunotherapy-resistant cancers. The translational research included the analysis of blood and tumor samples from patients in the GOBLET (pancreatic ductal adenocarcinoma (PDAC) and other gastrointestinal cancers) and AWARE-1 (breast cancer) studies. Analyses revealed consistent immune activation signatures, including: Upregulation of interferons, CXCL9/10/11, and PD-L1 Conversion of immunologically 'cold' tumors into 'hot' phenotypes Expansion and mobilization of tumor-infiltrating lymphocyte (TIL) clones in the blood, which correlates with a reduction in tumor size Modulation of the tumor microenvironment (TME) to enhance responsiveness to immune therapies "This robust data set, amassed from several studies in cancers that have historically resisted immunotherapeutic approaches, provides definitive validation of pelareorep's immune-mediated mechanism of action," said Dr. Thomas Heineman, Chief Medical Officer of Oncolytics. "We observed tumor biopsy-confirmed virus replication, immune cell activation, and the recruitment of cytotoxic T cells into the TME – all consistent with the durable responses observed in patients with metastatic PDAC and HR+/HER2- breast cancer who were treated with pelareorep." "The collection of data here show that pelareorep works how a cancer immunotherapy should work," said Jared Kelly, Chief Executive Officer of Oncolytics. "Pelareorep is a versatile product candidate with strong platform potential to enhance immunological responses in multiple indications, including hard-to-treat cancers. Such compelling findings should be exciting to strategic partners focused on finding a platform immunotherapy in large indications with high unmet medical needs." The GOBLET study continues to enroll PDAC and anal carcinoma patients, and additional translational data readouts are expected next year. The Company expects these and its other clinical data to support its focused and aggressive regulatory path and serve as the biological foundation for registration-enabled studies in immunotherapy-resistant solid tumors. As regulatory conversations progress throughout the summer, the Company expects to provide an updated clinical timeline before the end of the third quarter. About Oncolytics Biotech Inc. Oncolytics is a clinical-stage biotechnology company developing pelareorep, an intravenously delivered immunotherapeutic agent. Pelareorep has demonstrated promising results in two randomized Phase 2 studies in metastatic breast cancer and Phase 1 and 2 studies in pancreatic cancer. It acts by inducing anti-cancer immune responses and promotes an inflamed tumor phenotype – turning "cold" tumors "hot" – through innate and adaptive immune responses to treat a variety of cancers. Pelareorep has demonstrated synergies with multiple approved oncology treatments. Oncolytics is currently conducting and planning combination clinical trials with pelareorep in solid malignancies as it advances towards registrational studies in metastatic breast cancer and pancreatic cancer, both of which have received Fast Track designation from the FDA. For more about Oncolytics, please visit: or follow the company on social media on LinkedIn and on X @ oncolytics. This press release contains forward-looking statements, within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended and forward-looking information under applicable Canadian securities laws (such forward-looking statements and forward-looking information are collectively referred to herein as "forward-looking statements"). Forward-looking statements contained in this press release include statements regarding Oncolytics' belief as to the potential, mechanism of action and benefits of pelareorep as a cancer therapeutic; our plans, objectives and strategies; our expectation that our data supports our focused and aggressive regulatory path and serves as the biological foundation for registration-enabled studies in immunotherapy-resistant solid tumors; our plans to advance pelareorep into registration enabling studies in metastatic breast cancer and pancreatic cancer; and other statements related to anticipated developments in Oncolytics' business and technologies. In any forward-looking statement in which Oncolytics expresses an expectation or belief as to future results, such expectations or beliefs are expressed in good faith and are believed to have a reasonable basis, but there can be no assurance that the statement or expectation or belief will be achieved. Such forward-looking statements involve known and unknown risks and uncertainties, which could cause Oncolytics' actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue research and development projects, the efficacy of pelareorep as a cancer treatment, the success and timely completion of clinical studies and trials, Oncolytics' ability to successfully commercialize pelareorep, uncertainties related to the research and development of pharmaceuticals, uncertainties related to the regulatory process and general changes to the economic environment. We may incur expenses or delays relating to events outside of our control, which could have a material adverse impact on our business, operating results and financial condition. Investors should consult Oncolytics' quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements. Investors are cautioned against placing undue reliance on forward-looking statements. The Company does not undertake any obligation to update these forward-looking statements, except as required by applicable laws. Company Contact Jon Patton Director of IR & Communication [email protected] Investor Relations for Oncolytics Mike Moyer LifeSci Advisors +1-617-308-4306 [email protected]
